Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E63.08 EPS (ttm)6.41 Insider Own0.50% Shs Outstand105.29M Perf Week0.32%
Market Cap42.55B Forward P/E27.83 EPS next Y14.52 Insider Trans-2.14% Shs Float77.55M Perf Month0.97%
Income743.00M PEG3.39 EPS next Q2.73 Inst Own70.90% Short Float4.36% Perf Quarter22.07%
Sales4.65B P/S9.15 EPS this Y85.10% Inst Trans-0.16% Short Ratio4.37 Perf Half Y10.00%
Book/sh38.96 P/B10.37 EPS next Y32.01% ROA13.00% Target Price467.86 Perf Year-17.64%
Cash/sh9.93 P/C40.71 EPS next 5Y18.62% ROE20.10% 52W Range329.09 - 592.59 Perf YTD-25.56%
Dividend- P/FCF40.43 EPS past 5Y44.90% ROI16.00% 52W High-31.80% Beta1.31
Dividend %- Quick Ratio3.10 Sales past 5Y55.00% Gross Margin91.40% 52W Low22.80% ATR10.06
Employees4300 Current Ratio3.40 Sales Q/Q21.40% Oper. Margin26.70% RSI (14)50.43 Volatility2.13% 2.36%
OptionableYes Debt/Eq0.09 EPS Q/Q0.00% Profit Margin16.00% Rel Volume0.84 Prev Close410.39
ShortableYes LT Debt/Eq0.09 EarningsNov 03 BMO Payout0.00% Avg Volume774.72K Price404.12
Recom2.30 SMA201.16% SMA50-0.49% SMA200-1.56% Volume658,600 Change-1.53%
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Sep-26-16 04:32PM  Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema
03:55PM  Regeneron, Sanofi Skin Disease Drug Under Priority Review
02:22PM  Regeneron Win Review for Dermatitis Drug (REGN) at Investopedia
07:15AM  FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme at bizjournals.com
03:24AM  Sanofi may win U.S. approval of $3 bln eczema drug by March Reuters
01:01AM  Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA GlobeNewswire
01:00AM  Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA PR Newswire
Sep-22-16 11:17AM  [$$] Teva, Allergan Pump Up the Pipelines at Barrons.com
Sep-21-16 03:08PM  Regeneron, Teva Collaborate to Develop Chronic Pain Drug
11:05AM  Ioniss Orphan Drug in Third Phase of Clinical Trials
08:39AM  Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
12:30AM  Regeneron to Collaborate With Teva for Fasinumab Drug (REGN, TEVA) at Investopedia
Sep-20-16 07:01AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
07:00AM  Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain Business Wire
07:00AM  Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain PR Newswire
Sep-19-16 08:25AM  RBC Says These 4 Top Biotechs Could Have Big Upside Potential at 24/7 Wall St.
Sep-18-16 02:57PM  5 Trade Ideas for Monday: TD Ameritrade, AstraZeneca, Costco, International Paper and Regeneron
Sep-16-16 12:49PM  Vertex: Did Management Deliver Investors a Backhanded Slap? at Barrons.com
Sep-14-16 04:28PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Sep-13-16 11:52AM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : September 13, 2016
Sep-12-16 08:30AM  Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors PR Newswire
08:13AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : September 12, 2016
Sep-06-16 08:15AM  A $14,000 Price Tag For A Cholesterol Drug Can Be A Bargain at Forbes
Sep-03-16 02:50PM  3 Biotech Stocks to Buy in September at Motley Fool
09:35AM  3 Large-Cap Stocks to Buy in September at Motley Fool
Sep-01-16 03:51PM  3 Stocks That Turned $3,000 Into $30,000 or More! at Motley Fool
10:04AM  Regenerons Growth Opportunities: Praluent, Sarilumab, and Dupilumab
09:30AM  Regeneron Announces Upcoming 2016 Investor Conference Presentations PR Newswire
08:07AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : September 1, 2016
08:04AM  Restricted Access Continues to Impact Praluent Sales in 2016
Aug-31-16 06:09PM  3 Beaten-Up Biotech Stocks: Are They Bargains? at Motley Fool
11:53AM  Why Eylea Could Face Tough Competition in 2016
11:53AM  What Are Analysts Recommendations for Regeneron in 2016?
11:53AM  Regenerons Valuation Multiples Compared to Its Peers
10:24AM  Biotech: In Unfamiliar Territory? at Barrons.com
10:13AM  The Medicines Co. Offers Update on Dyslipidemia Programs
Aug-29-16 04:46PM  [$$] Regeneron Can Generate Big Returns for Investors at Barrons.com
02:39PM  How Will Regeneron (REGN) Stock React to Cholesterol Drug Trial Success?
09:33AM  Regeneron/Sanofi Present Positive Phase III Praluent Data
09:26AM  Stocks to Watch: Mylan, Herbalife, Caesars Entertainment at The Wall Street Journal
02:00AM  Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016 PR Newswire
Aug-27-16 09:12AM  These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year at Motley Fool
Aug-24-16 03:00PM  Regeneron ranks as one of most innovative companies by Forbes at bizjournals.com
02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug-23-16 09:48AM  Regeneron Stock Up on BARDA Deal for MERS Antibodies
Aug-22-16 11:56AM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : August 22, 2016
08:30AM  Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus PR Newswire
Aug-19-16 04:19PM  Hunting For Biotech Stocks? Understand The Earnings Formula First
11:04AM  Horizons Orphan Drug Business Faces These Opportunities
07:00AM  No Pain, Potential for Lots of Gain at Morningstar
Aug-16-16 11:00AM  Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says at Bloomberg
Aug-14-16 04:49PM  3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions
Aug-12-16 09:30AM  The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
08:53AM  How to Play a Nasdaq Breakout
Aug-11-16 05:30PM  Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
05:05PM  NFL doing everything it can on concussions, Dan Marino says at CNBC
02:41PM  Hall of Famer Dan Marino on his investments
01:05PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : August 11, 2016
01:04PM  REGENERON PHARMACEUTICALS INC Financials
09:31AM  Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Aug-09-16 10:34AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
09:08AM  What Do Analysts Recommend for Regeneron after 2Q16 Earnings?
Aug-08-16 05:46PM  How Did Regeneron Perform in 2Q16?
01:46PM  How Did Regenerons Revenue and Earnings Look in 2Q16?
Aug-05-16 01:44PM  Regeneron: The Downside of High Expectations at Barrons.com
06:55AM  Regeneron Pharma downgraded by Robert W. Baird
Aug-04-16 04:44PM  Regeneron Stock Dips As Earnings Beat And Revenue Lags
01:44PM  [$$] Regeneron's Revenue Jumps on Sales of Eye Treatment Eylea at The Wall Street Journal
12:59PM  Keep Calm and Spend On, Regeneron at Bloomberg
11:33AM  Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View
11:14AM  Edited Transcript of REGN earnings conference call or presentation 4-Aug-16 12:30pm GMT
11:03AM  Regeneron: EPS Beat and 21% Revenue Growth Not Enough to Impress; Shares Down 4.4% at Barrons.com
10:48AM  Regeneron sticks by 2016 growth forecast for Eylea, shares fall
10:40AM  Merrill Lynch Says the Time to Put Money Into Biotech Is Now at 24/7 Wall St.
08:59AM  The Market In 5 Minutes: Bank Of England Cut Interest Rates For The First Time In 7 Years
08:22AM  Regeneron (REGN) Beats on Q2 Earnings, Retains Eylea View
07:20AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q2 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:43AM  Regeneron tops 2Q profit forecasts
06:42AM  Eylea sales lift Regeneron quarterly revenue
06:30AM  Regeneron Reports Second Quarter 2016 Financial and Operating Results PR Newswire
05:35AM  Sizzling S&P sectors for summer
Aug-03-16 09:36AM  5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Aug-02-16 10:21AM  Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts
08:30AM  Regeneron and Adicet Bio Announce Strategic Collaboration to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics PR Newswire
Aug-01-16 11:58AM  Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
09:58AM  Regeneron Is Regenerating Lost Profits
09:09AM  Vertexs Orkambi to Treat Cystic Fibrosis Drives Companys Growth
02:00AM  Sanofi and Regeneron Announce EMA Acceptance for Review of Marketing Authorisation Application for Sarilumab PR Newswire
Jul-31-16 11:14AM  BioMarin: Why So Many Buy Recommendations?
Jul-29-16 09:43AM  Better Buy: Regeneron Pharmaceuticals vs. Pfizer at Motley Fool
Jul-26-16 05:17PM  What Do Analysts Recommend for Shire?
Jul-25-16 11:05AM  Understanding Improvement in Vertex Pharmaceuticalss PE Multiple
Jul-22-16 07:53PM  Whats Been Beating down the Fidelity Growth Company Fund in 2016?
07:00PM  Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
01:12PM  What Do Analysts Recommend for United Therapeutics?
Jul-21-16 03:56PM  Analysts Gauge Alexion Pharmaceuticals Return Potential
Jul-20-16 12:03PM  Why I Bought Shares of Regeneron Pharmaceuticals Inc. Last Week at Motley Fool
Jul-19-16 07:21AM  3 Biotech Stocks to Buy and Hold at Motley Fool
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 02Sale549.0343,34823,799,539500,000Dec 04 04:13 PM
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM